Aventis Pharma S.a.

Marc Antoine Perrin

Pascal Billot

Carole Neves

Sylvaine Lafont

Jacques Bourget

Bernd Janocha

Serge Mignani

Michel Tabart

Michel Cheve

The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure:and as characterized herein by powder X-ray diffraction patterns as form A and form B, processes for preparing form A from the purified amorphous form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a processes for preparing form A by heating monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a pharmaceutical composition comprising form A, a pharmaceutical composition comprising form A and form B or monohydrated form C, a pharmaceutical composition comprising form A, form B and monohydrated form C, a method for treating a bacterial infection with form A, a method for treating a bacterial infection with form A and form B or monohydrated form C, and a method for treating a bacterial infection with form A and form B and monohydrated form C.

Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid

The present invention comprises monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structureand as herein defined by powder X-ray diffraction, processes for preparing monohydrated form C from amorphorous (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid or form A of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, pharmaceutical compositions comprising monohydrated form C, pharmaceutical compositions comprising monohydrated form C and form A or form B of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, pharmaceutical compositions comprising monohydrated form C, form A and form B, methods for treating bacterial infection with monohydrated form C, methods for treating bacterial infection with monohydrated form C and form A or form B, methods for treating bacterial infection with monohydrated form C, form A and form B, and a process for the preparation of form A from monohydrated form C.

Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6 methoxyquinolin-4-propyl]-1-[2-2-thienylthio)ethyl] piperidine-3-carboxylic acid

Growing community of inventors

Jouy en Josas, France

Marc Antoine Perrin